Diabetes

By Tammy Lovell April 16, 2019
When Siddharth Sharma received a diagnosis of type 1 diabetes, his first reaction was to create a spreadsheet of health data. “As an engineer, I did the most logical thing when I came back from the doctor with my insulin and my needles; I got out my laptop and opened a spreadsheet. I started logging everything to find out what was going on,” he tells MobiHealthNews. However, Sharma knows that not...

Photo credit: Biolinq

By Laura Lovett March 28, 2019
This morning Biolinq, a digital health company specializing in minimally invasive continuous glucose monitoring, raised $4.75 million in extended Series A financing. This new capital was led by JDRF T1D Fund, Aphelion Capital and LifeSci Venture Partners.  This latest funding announcement will build on the $10 million the company raised in November of 2017, bringing the total Series A capital to...
By Laura Lovett March 25, 2019
On Friday, Senseonics, maker of the implantable continuous glucose monitoring system Eversense, announced a new program geared towards patients with high-deductible insurance plans or plans that don’t cover the full cost of the CGM.  The new program, called Eversense Bridge, charges patients $99 for the Eversense CGM system, in addition to the cost of the sensor placement by their provider....
By Jonah Comstock March 12, 2019
San Francisco-based digital chronic disease managment company Omada Health announced today that it will add fully integrated, cellular-connected glucometers and blood pressure cuffs to its offerings for Type 2 diabetes and hypertension, respectively. The devices are FDA-cleared and can be mailed to program members. The glucometer will come with as many free test strips as users need, the company...
By Dave Muoio March 11, 2019
New research set to be presented next week at the American College of Cardiology’s 68th Annual Scientific Session describes how the camera on a smartphone could be used to screen for Type 2 diabetes. Diabetes is associated with changes to how blood flows through a person’s blood vessels, an effect that researchers from UCSF suggest could be used to detect early changes. By applying a deep...
By Jonah Comstock March 11, 2019
At SXSW in Austin this weekend, consumer genomics company 23andMe unveiled its latest test, a predisposition report on Type 2 diabetes. The test, which has not undergone FDA clearance and does not purport to diagnose a condition, is designed to help people understand when they’re at a higher-than-normal risk for Type 2 diabetes so they can alter their lifestyle. To assist with the latter piece,...
By Laura Lovett March 5, 2019
This morning Senseonics, an implantable glucose sensor company, announced that data from its Eversense continuous glucose monitor will be integrated into the Glooko diabetes management platform.  This means that users of the Eversense CGM and app will now be able to sync it with the Glooko online platform and app, and be able to see historical blood glucose-related data as well as get updates...
By Laura Lovett February 28, 2019
For folks managing their diabetes with Dexcom, Siri can now answer one more question: What is my glucose level? This morning Dexcom announced a slew of new companion app features for the Dexcom G6 continuous glucose monitoring system, including the ability for Siri to read a user’s glucose level out loud and display graphs directly on the lock screen.  The app, which was released in 2018, will...
By Dave Muoio February 25, 2019
Earlier this month, Hygieia’s d-Nav Insulin Guidance Service — an app that titrates insulin doses for individual Type 2 diabetes patients, regardless of their regimen type — received 510(k) clearance from the FDA. The cloud-based service leverages proprietary algorithms, users’ individual blood glucose data and a small team of in-house health professionals to generate and deliver insulin dosage...
Novo Nordisk insulin pens
By Jonah Comstock February 20, 2019
Novo Nordisk’s connected insulin pens will integrate with the Abbott Freestyle Libre system, allowing Freestyle Libre users to see data about their insulin alongside their glucose readings, the companies announced this morning. "Lack of reliable information is a cause of huge frustration for many people with diabetes and their doctors," Anders Dyhr Toft, CVP of commercial innovation at Novo...